• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Check-Cap Ltd.

    9/5/25 4:30:29 PM ET
    $CHEK
    Medical Electronics
    Health Care
    Get the next $CHEK alert in real time by email
    6-K 1 ea0256194-6k_checkcap.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For September, 2025

     

    Commission File No. 001-36848

     

    Check-Cap Ltd.

     

    Check-Cap Building

    Abba Hushi Avenue

    P.O. Box 1271

    Isfiya, 30090

    Mount Carmel, Israel

    (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES.)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

    This Form 6-K is being incorporated by reference into Check-Cap Ltd.’s Registration Statements on Form F-3 (File No. 333-262401) and Form S-8 (File No. 333-203384, 333-226490 and 333-259666) filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Nasdaq Letter

     

    As previously disclosed, on May 21, 2025, the Nasdaq Listing Qualifications Department notified Check-Cap Ltd. (the “Company”) that it no longer met the periodic filing requirement for The Nasdaq Stock Market (“Nasdaq”) under Nasdaq Listing Rule 5250(c)(1), which requires the Company to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”). The Company filed its Annual Report on Form 20-F for the year ended December 31, 2024 (the “Form 20-F”) on August 27, 2025. On September 3, 2025, the Company received a letter from Nasdaq that, based on the filing of the Form 20-F, it has been determined that the Company complies with Nasdaq Listing Rule 5250(c)(1). Accordingly, this matter is now closed.

     

    Receipt of Nasdaq Deficiency Letter

     

    On September 3, 2025, the Company received a deficiency letter (the “Letter”) from the Nasdaq Listing Qualifications Department notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company maintain a minimum of $2,500,000 in stockholders’ equity. The Letter further stated that the Company has 45 calendar days, or by October 20, 2025, to submit a plan (the “Plan”) to regain compliance with respect to the deficiency identified in the Letter. If Nasdaq accepts the Plan, it may grant an extension of up to 180 calendar days from the date of the Letter for the Company to evidence compliance. If Nasdaq does not accept the Plan, the Company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel. The Company will work diligently to submit the Plan promptly and take the necessary steps to regain compliance as soon as practicable.

     

    Asset Purchase Agreement

     

    On September 5, 2025, the Company took a bold step forward in the fast-growing world of food innovation. The Company entered into an Asset Purchase Agreement with Parea LLC, a Pennsylvania limited liability company (the “Seller”), to acquire all right, title, and interest in a contract granting exclusive Ghost Kitchen franchise rights across the state of New Jersey.

     

    Ghost Kitchen represents the future of dining—state-of-the-art kitchens that operate in non-retail environments, delivering a diverse mix of restaurant experiences designed exclusively for take-out and delivery. Through this acquisition, the Company gains the rights to drive franchise sales, deliver hands-on training, and provide full support to franchisees throughout New Jersey.

     

    Under the Ghost Kitchen Area Representative Agreement (the “Agreement”), the Company is entitled to share directly in the growth of this innovative model—receiving 50% of all initial franchise fees and 50% of all ongoing royalties actually paid by New Jersey franchisees. This structure gives the Company a powerful, recurring revenue stream tied to the expansion of Ghost Kitchen across one of the nation’s most densely populated and strategically important states.

     

    As consideration for these valuable assets, the Company issued to the Seller 1,169,596 ordinary shares of the Company.

     

    This transaction positions the Company at the forefront of the rapidly expanding Ghost Kitchen movement, unlocking a high-growth opportunity in one of the most dynamic food service markets in the United States.

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Check-Cap Ltd.
         
    Date: September 5, 2025 By: /s/ David Lontini
        Name:  David Lontini
        Title: Interim CEO

     

     

    2

    Get the next $CHEK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHEK

    DatePrice TargetRatingAnalyst
    8/9/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CHEK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MBody AI and Check-Cap Enter into Definitive Merger Agreement

    Merger to Create Combined Company Focused on Embodied AI for the Autonomous Workforce ISFIYA, ISRAEL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- MBody AI ("MBody AI") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Agreement and Plan of Merger (the "Merger"). If the Merger is approved by Check-Cap shareholders, it will create a combined company focused on embodied AI for the autonomous workforce. Check-Cap's legacy business will continue its research and development activities as part of the combined company. MBody AI is a market-leading artificial intelligence ("AI") company redefining the future of work through embodied

    9/12/25 5:39:51 PM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap claims BMO's Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime

    Check-Cap Ltd. Issues Strong Condemnation of MediPharm Labs Chairman Chris Taves for Fabricated Defamatory Statements Press Releases Taves Times his Attack to Commence 23 Minutes before the Start of Shabbat to Delay the Company from Responding ISFIYA, ISRAEL, June 04, 2025 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (NASDAQ:CHEK) ("Check-Cap" or the "Company"), a clinical-stage medical diagnostics company incorporated in Israel, today publicly condemned MediPharm Labs Corp. (LABS) ("MediPharm Labs") and its Chairman, Chris Taves, Head of Asia for BMO Capital Markets, for disseminating derogatory, false, and misleading statements about Check-Cap during a profoundly sensitive and challenging time

    6/4/25 7:00:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

    Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion  Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board  Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex

    5/14/25 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

    HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $3.00 from $4.00 previously

    8/9/21 6:35:25 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap downgraded by Dawson James with a new price target

    Dawson James downgraded Check-Cap from Buy to Neutral and set a new price target of $2.00

    3/17/21 12:12:30 PM ET
    $CHEK
    Medical Electronics
    Health Care

    HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

    HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $4.00 from $1.50 previously

    3/16/21 6:31:50 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    SEC Filings

    View All

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    9/12/25 4:38:16 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    9/5/25 4:30:29 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form 20-F filed by Check-Cap Ltd.

    20-F - Check-Cap Ltd (0001610590) (Filer)

    8/26/25 8:59:38 PM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Leadership Updates

    Live Leadership Updates

    View All

    Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting

    Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO, Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, today issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental.  Symetryx discusses its concerns around the actions of the Board in its evaluation

    11/28/23 11:56:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap Appoints Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs

    ISFIYA, Israel, Sept. 1, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs. Dr. Brenner-Lavie will be responsible for leading the Company's overall clinical strategy and implementation as well as driving the Company's clinical direction, including innovation. "Dr. Brenner-Lavie has a proven track record of clinical strategy dev

    9/1/21 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Financials

    Live finance-specific insights

    View All

    Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

    Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion  Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board  Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex

    5/14/25 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Keystone Dental Group Granted Patent from USPTO for Nexus IOS Solution

    IRVINE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Osteon Medical, a subsidiary of Keystone Dental Holdings ("Keystone Dental" or the "Company"), today announced the United States Patent and Trademark Office (USPTO) has granted the Company a patent for its innovative Nexus IOS solution. The Nexus iOS Scan Gauge technology allows implant dentists to perform direct full-arch implant scans using an Intraoral Scanner (IOS) with predictable and passive fitting prosthetic outcomes. This technology replaces the traditionally manual impression-taking process through a faster, cost-effective, and accessible workflow. The Nexus iOS Scan Gauge technology is now the only patented elongated body scan

    10/18/23 4:05:00 PM ET
    $CHEK
    Medical Electronics
    Health Care

    Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement

    Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions Keystone 2022 revenues exceeded $60 million The combined company will trade on the NASDAQ with the ticker "KSD" Investor conference call and webcast scheduled for 8:30 a.m. ET on Thursday, August 17th IRVINE, Calif. and BURLINGTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings, Inc. ("Keystone Dental") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Busin

    8/16/23 5:08:47 PM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

    SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

    4/8/24 7:35:32 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form SC 13D filed by Check-Cap Ltd.

    SC 13D - Check-Cap Ltd (0001610590) (Subject)

    4/1/24 9:26:38 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

    SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

    12/18/23 6:07:13 AM ET
    $CHEK
    Medical Electronics
    Health Care